It is observed in many reports that the abnormal expression of LOXL2 in different types of malignancies is linked with EMT, metastasis, chemoradiotherapy resistance, worse prognosis, and progression of a tumor [40–42]. This evidence concerns the gene LOXL2 and neoplasm.